Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
I am not focused on today's price movement of the stock but the pattern from the end of 2017.
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
Uber's crash on earnings does not mean the stock is totaled according to analysts covering the stock.
Announcement of a settlement of a lead paint legal tussle that had gone on for nearly two decades gave NL shares a boost Thursday.
The loss of clients is a primary concern here.
Turbulence with Boeing's MAX jets jolts suppliers.
The Federal Aviation Administration has declined to set a timeline on when it will lift its order prohibiting the troubled aircraft from flying.